Teva, Medincell granted FDA review for long-acting antipsychotic
Source: SeekingAlpha
2026-02-21 09:09:02 ET
More on Teva Pharmaceutical, Royalty Pharma, etc.
- Teva Pharmaceutical Industries Limited (TEVA) Discusses Duvakitug IBD Phase 2b Maintenance Top-Line Results - Slideshow
- Teva Pharmaceutical Industries Limited (TEVA) Discusses Duvakitug IBD Phase 2b Maintenance Top-Line Results Transcript
- Royalty Pharma: 2025 Financial Performance And Strategic Outlook
- Corcept falls as appeals court sides with Teva in Korlym patent dispute
- Teva, Sanofi report durable phase 2b efficacy for duvakitug in ulcerative colitis, Crohn’s disease
Read the full article on Seeking Alpha
For further details see:
Teva, Medincell granted FDA review for long-acting antipsychotic
Medical Intelligence Technologies Inc
NASDAQ: MDCLF
MDCLF Trading
100.0% G/L:
$6.9757 Last:
2,000 Volume:
$0 Open:
MDCLF Latest News
November 11, 2025 02:00:00 am
Medincell Appoints Dr Grace Kim, Chief Strategy Officer, U.S. Finance, to Advance into Next Stage of US Capital Growth
November 10, 2025 12:00:00 pm
Medincell to Join MSCI World Small Cap Index, a Leading Global Benchmark
February 10, 2025 02:00:00 am
Completion of the Pivotal Phase 3 Trial for Olanzapine LAI in Schizophrenia Conducted by Teva Pharmaceuticals
